ALFA Filings
Every announcement, straight from the exchange
Every Biocon product launch announcement on NSE and BSE, newest first, each with its own page.
Time
2 announcements with these filters
Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.
Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.